UNSPSC 51284040: Rolitetracycline nitrate

This classification denotes a tetracycline antibiotic with the molecular structure 2C27H33N3O8.2HNO3.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, TG72BS085Y chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-n-(1-pyrrolidinylmethyl)-, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, mononitrate (salt), sesquihydrate, but more commonly known as rolitetracycline nitrate, which bears US NIH Compound Identifier 5282178.

UNSPSC 51284040 Rolitetracycline nitrate is a Commodity code that nominally covers a specific tetracycline antibiotic, but recent state and local procurement activity under this code shows limited direct relevance to the taxonomy name. The most recent opportunities tagged to this code involve pharmaceutical procurement and drug-related products, though the actual items being solicited — Doxycycline Hyclate and Ciprofloxacin tablets in one case, and Naloxone and drug deactivation systems in another — do not correspond to rolitetracycline nitrate. State and local health departments and county government agencies are the primary issuing bodies, reflecting their roles in emergency preparedness, pharmaceutical stockpiling, and community health service delivery. The code appears to function as a catch-all or mislabeled category for miscellaneous pharmaceutical and health-related products rather than a precise match to specific drug formulations.

Activity is concentrated in the Southeast and Midwest. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC on August 28, 2026, to supply Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets over a 12-month initial term with two renewal options. Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries beginning July 26, 2023, and a two-year contract term plus one-year renewal option. Both opportunities reflect inventory-based health procurement rather than clinical prescribing. Businesses pursuing this code should verify actual commodity classification with issuing bodies and consider that the code may not consistently map to specific product families in active procurement.